KRAS and colorectal carcinoma: In mouse orthotopic xenograft models derived from CRC patients, MCLA-158 treatment not only reduced the size of the primary tumor but also effectively suppressed metastasis, including that of KRAS mutant tumors resistant to Cetuximab.